ERBB2 and breast cancer: Triple negative breast cancers (TNBCs) account for around 15% of all breast cancers and are pathologically characterized by the negative expression of estrogen receptor (ER) and progesterone receptor (PR) as well as the aberrant expression of human epidermal growth factor receptor 2 (HER2) [1].